A study examining ketamine intravenous therapy (KIT) for depression reported promising outcomes. From 2016-2020, over 9,000 patients from across the U.S. received KIT. Using the PHQ-9 scale, 53.6% of the 537 patients assessed showed a significant response to KIT 14-31 days post-induction, with a 50% or more reduction in PHQ-9 scores. Additionally, 28.9% achieved remission, marked by a PHQ-9 score below 5. The treatment’s impact was profound, with an effect size of d=1.5.
Positive outcomes were also noted for patients with suicidal thoughts, with 73% showing a decrease post-treatment. However, 8.4% had increased depressive symptoms, while 6.0% had heightened suicidal ideation post-induction.
The KIT response was consistent across different depression severities, but those with more severe symptoms showed slightly greater PHQ-9 score reductions. The odds of achieving remission were inversely linked to depression severity. Importantly, those responding to KIT had high chances of sustained improvement—80% at four weeks and 60% at eight weeks post-induction.
Ketamine intravenous therapy (KIT) is an emerging and promising treatment for depression. Recent studies have underscored its effectiveness, and at Luvita, we’ve observed a response rate exceeding 80%.
Understanding the science and nuances behind a treatment is crucial for making informed healthcare decisions. KIT works differently than traditional antidepressants, targeting specific pathways in the brain that may offer relief in cases resistant to other treatments.
For those interested in exploring evidence-based treatments for depression, we recommend familiarizing yourself with KIT. Luvita is not only a provider of this innovative treatment, but also an educational resource. Our primary objective is to ensure patients are well-informed, comfortable, and confident in their treatment choices.
Curious about how KIT could potentially benefit you or a loved one? Consider booking a free consultation with us to learn more: Luvita